---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013803"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:49:00.103548+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months

## Summary
- Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.
- 95% CI lower bound of 12.5 months and 99% CI lower bound of 10.8 months shown.
- New partial response (>=30% tumor reduction) observed after >20 months on treatment.
- Longest-surviving patient reached 24.3 months and completed 32 cycles of therapy.
- Potential FDA decision for ateganosine as early as next year.

## SEC filing metadata
- accession: 0001641172-25-013803
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225013803/0001641172-25-013803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225013803/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013803
- JSON: https://secwatch.observer/filing/0001641172-25-013803.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013803.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.